Researcher Spotlight: Harsh Shah, DO The University of Utah Immunotherapy with checkpoint inhibitors is commonly used for treatment of Hodgkin lymphoma after relapse. While many patients initially respond to these therapies, the development of resistance is common over time. Dr.…
Researcher Spotlight: Christine Ryan, MD Dana-Farber Cancer Institute Upfront treatment of mantle cell lymphoma (MCL) typically involves an aggressive approach to treatment that offers the best chance of a durable and lasting response. Dr. Ryan is investigating a new first-line…
Researcher Spotlight: Niloufer Khan, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Health Equity Initiative Cutaneous T-cell lymphoma (CTCL) is a chronic form of cancer that causes pain, discomfort, and itchiness that can affect patients’ well-being and quality of life. “Itch…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Tomohiro Aoki, MD, PhD UNIVERSITY HEALTH NETWORK Peykoff Initiative Investigator Cancer cells exist within a greater tumor microenvironment that is modified by tumor cells to support their growth and proliferation. These cells can also modify their environment to…
Researcher Spotlight: Erin Parry, MD, PhD DANA-FARBER CANCER INSTITUTE Dr. Parry’s research is centered at the intersection of genomics and cancer immunotherapy, with a focus on B cell lymphomas. Her LRF research project is aimed at understanding the processes that…
Researcher Spotlight: Wen-Hsuan Wendy Lin, MD, PhD COLUMBIA UNIVERSITY Peripheral T-cell lymphomas (PTCL) represent a group of aggressive blood cancers with poor outcomes. A common phenomenon in PTCL is the development of a proinflammatory microenvironment, in which lymphoma cells recruit…
Researcher Spotlight: Andrew Jallouk, MD, PhD Vanderbilt University Medical Center Errol M. Cook Memorial Scholar Chimeric antigen receptor (CAR) T-cell therapy represents a highly effective treatment option for many types of lymphoma. Currently available CAR T-cell therapies are engineered on…
Researcher Spotlight: Alexander Boardman, MD Memorial Sloan Kettering Dobosh Family Scholar Treatment of lymphoma has been revolutionized by the emergence of CD19-directed chimeric antigen receptor (CAR) T-cell therapies, but many patients still relapse after treatment. Dr. Boardman’s LRF research seeks…
